The global menopause treatment market is estimated to be worth over US$ 13.3 billion in 2022, based on the most current industry analysis by Future Market Insights. Over the course of the projection period, the market is anticipated to increase at a compound annual growth rate (CAGR) of over 5.5%, with an estimated worth of US$ 22.9 billion in 2032.
Side effects are a result of the drug used in hormone therapy, which includes progestin, estrogen, and tibolone. Vaginal bleeding, weight gain, breast soreness, endometrial hyperplasia, and other issues are common among women, which is giving manufacturers of pharmaceuticals a chance to enhance medicine formulations that can treat all of these issues simultaneously.
In addition, osteoporosis cases are relatively common in menopausal women, and bone fractures are particularly common. Because menopause and low estrogen levels are directly related, menopause is also thought to be a prevalent cause of osteoporosis. Women are more likely to break than men.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15766
Menopause treatment market expansion is anticipated to be driven by increased investment in R&D and healthcare settings to create innovative therapies and drugs with a focus on low-cost product development and fewer side effects throughout the projected period.
Additionally, a lot of startups are concentrating on funding to support various initiatives. More tech-enabled businesses are vying for funding to support the digital health of women.
Key Takeaways:
- Hormone therapy is the leading segment by product, and holds approximately 7% market value share in 2021, due to higher adoption and easier adoption of availability of medications that are used in hormone therapy.
- By route of administration, numerous studies demonstrate that women are substantially better protected against cardiovascular issues, with both heart attacks and strokes occurring at significantly lower rates when oral medications are prescribed. Hence, oral route of administration holds a market share of 0% in 2021.
- By distribution channel, retail sales are leading in the global menopause treatment market, and are expected to continue to do so with a projected CAGR of 6% during the forecasted years. Retail sales include retail pharmacies, drug stores, supermarkets, and hypermarkets, which are easily accessible and offer services like home delivery, making it the most lucrative among others.
- South Asia held the largest market share in the global menopause treatment market and estimated to grow at a CAGR of close to 6% due to the presence of a prestigious society and institutes that are educating and creating awareness among the population.
“Government campaigns creating awareness on women’s health and menopause is set to propel the sales of menopause treatment products across the globe,” says an analyst of Future Market Insights.
Market Competition
The market for menopause treatment is fragmented with well-established players, local and new entrants within the market sphere. Key players have initiated product launches with additional patient requirements addressing major issues related to side effects, attained regulatory approvals, and increased their manufacturing facilities.
- Theramex and Endoceutics expanded their initial contract in February 2022 to include the sale of Intrarosa® (prasterone) in Australia.
- In 2018, Glenmark Pharmaceuticals received the final approval from the US health regulator for a generic version of Nordisk Inc.’s VAGIFEM, for menopause symptoms.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the menopause treatment market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032. The global menopause treatment market is segmented in detail to cover every aspect of the market and presents a complete market intelligence approach to the reader.
The research study is based on product– (hormone therapy [combination, Tibolone, progestin-only medicines, and estrogen-only medicines] and non-hormonal therapy [gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), others]), route of administration (topical, injectable, and oral), and distribution channel (institutional sales [hospitals and specialty clinics], retail sales [retail pharmacies, drug stores, supermarkets/ hypermarkets, and online sales), across seven key regions of the world.
Key Segments :
By Product:
- Hormone TherapyCombination
Tibolone
Progestin-Only Medicines
Estrogen-Only Medicines
- Non-Hormonal TherapyGabapentinoids
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)
Selective Serotonin Reuptake Inhibitors (SSRI)
Others
By Route of Administration:
- Topical
- Injectable
- Oral
By Distribution Channel:
- Institutional SalesHospitals
Specialty Clinics
- Retail SalesRetail Pharmacies
Drug Stores
Supermarkets/ Hypermarkets
- Online Sales